MET and non-small cell lung carcinoma: Using the MET inhibitor onartuzumab plus erlotinib, an improved progression-free survival (PFS) and a better overall survival (OS) was seen in immunohistochemically MET-positive NSCLC patients, while a worse outcome was observed in MET-negative patients treated with onartuzumab.[10] However, recent published results by Spigel et al [11]from the III randomized trial of Onartuzumab plus Erlotinib versus Erlotinib trial failed to show similar results.